# Biomatter Secures $18 Million to Advance Enzyme Design Efficiency

> With $18 million in new funding, Biomatter is set to revolutionize enzyme design by delivering custom solutions directly to clients, enhancing efficiency in industries reliant on biotechnological innovations.

**Source**: bioxconomy.com | **Published**: 2026-11-13 | **Type**: article

## Key Facts

- Biomatter secured $18M in Series A funding, indicating strong investor confidence in enzyme innovation.
- 25+ enterprise customers show Biomatter's competitive edge in customer validation over platform claims.
- Unique enzyme designs, like the SAM-free methylase, highlight Biomatter's technological advantages in biotech.
- Plans for a new facility aim to reduce development cycles from weeks to days, enhancing operational efficiency.
- Positive investor relations foster re-investment, revealing strategic importance of transparency and collaboration.

## Summary

Biomatter, a biotechnology firm based in Vilnius, Lithuania, has successfully secured $18 million in an oversubscribed Series A funding round. This capital will enable the company to scale its innovative approach to enzyme design, which is already being utilized in products from major players such as AstraZeneca, BASF, and Sanofi. The funding round was led by Astanor, with participation from existing investors including UVC Partners, Inventure, and Metaplanet. This development is significant as it highlights the growing demand for custom-designed enzymes, driven by advancements in artificial intelligence and a shift towards more efficient biotechnological solutions.

Biomatter distinguishes itself by designing enzymes based on the desired chemical reaction rather than relying on natural enzyme templates. This method leverages extensive proprietary data, enabling the company to achieve substantial structural innovations rather than merely refining existing enzymes. The company’s enzymes have already been integrated into commercial products, such as Thermo Fisher Scientific's Invitrogen SuperScript V Reverse Transcriptase, which benefits from enhanced oxidation resistance. Another notable application is in mRNA vaccine manufacturing, where Biomatter has engineered a methylase that eliminates the need for a costly additive commonly required by natural methylases.

The company's strategy of focusing on customer relationships before seeking investment has proven effective. CEO Laurynas Karpus emphasized that demonstrating a solid customer base—over 25 enterprise clients and more than 50 enzymes delivered—was critical in attracting investors. This approach shifts the conversation from theoretical platform capabilities to tangible business outcomes, which is increasingly important in a competitive landscape where many firms tout similar technological advancements.

The new funding will facilitate the establishment of a 2,000 square meter design-and-testing facility in Vilnius, expected to open in 2027. This facility aims to streamline the design-to-lab process, significantly reducing development cycles from weeks to days. Additionally, the investment will enhance Biomatter's commercial operations and expand its presence in the U.S. market, where approximately half of its customers are located. This expansion aligns with broader trends in the biotech sector, where companies are increasingly seeking to localize production and development to enhance responsiveness to market needs.

Biomatter's approach to investor relations also sets it apart. The company treats its investors as integral members of the operational team, fostering transparency and collaboration. This strategy has cultivated a supportive investor base that is willing to reinvest, reflecting a strong alignment of interests. Karpus's focus on specific requests for assistance—such as introductions and hiring—rather than general support, has contributed to this positive dynamic.

As the biotechnology sector continues to evolve, Biomatter’s success signals a potential shift towards more customer-centric business models. Companies that can demonstrate clear value through established customer relationships may find it easier to secure funding and market traction. This trend could lead to a more competitive landscape where the ability to deliver practical, efficient solutions becomes paramount. As firms like Biomatter refine their offerings and expand their capabilities, the implications for the broader market could include accelerated innovation cycles and a greater emphasis on collaboration between biotech firms and their enterprise customers.

## Entities

- **Companies**: Biomatter, AstraZeneca, BASF, Sanofi, Thermo Fisher Scientific, Invitrogen, Astanor, UVC Partners, Inventure, Metaplanet
- **Products**: SuperScript V Reverse Transcriptase
- **Technologies**: AI-designed enzymes, mRNA vaccine manufacturing
- **People**: Laurynas Karpus
- **Organizations**: BioXconomy

## Key Concepts

enzyme design, AI in biotechnology, venture capital funding, commercial applications of enzymes, customer-driven business model, development cycles in biotech, investor relations, biotech partnerships

## Definitions

- **AI-designed enzymes**: Enzymes created using artificial intelligence to optimize their design for specific chemical reactions.
- **Series A funding**: The first significant round of business financing, typically used to scale operations and product development.
- **mRNA vaccine manufacturing**: The process of producing vaccines that use messenger RNA to instruct cells to produce a protein that triggers an immune response.
- **oxidation resistance**: The ability of a substance to resist degradation due to oxidation, which is important for the stability of biological products.
- **development cycles**: The time required to develop a product from conception to market readiness.

## Use Cases

- Improving oxidation resistance for shipping and storage of biological products
- Engineering methylases for cost-effective mRNA vaccine production
- Scaling enzyme production for enterprise customers
- Designing custom enzymes for specific chemical reactions
- Establishing a design-and-testing facility for rapid development
- Enhancing investor relations through active collaboration

## Frequently Asked Questions

**What is Biomatter's main business focus?**

Biomatter focuses on designing custom enzymes using AI technology, targeting specific chemical reactions rather than relying on natural enzyme templates.

**How much funding did Biomatter secure?**

Biomatter closed an oversubscribed Series A funding round, raising $18 million to support its growth and expansion efforts.

**What are some applications of Biomatter's enzymes?**

Biomatter's enzymes are used in various commercial products, including improving the stability of mRNA vaccines and enhancing the performance of existing biological products.

**How does Biomatter maintain relationships with investors?**

Biomatter treats its investors as part of the operating team, sharing both successes and challenges, and actively seeking their input on specific issues.

**What are Biomatter's future plans?**

Biomatter plans to open a new design-and-testing facility in Vilnius by 2027, which will help streamline its development processes and expand its commercial presence.

## Links

- [Read on Welcome.AI](https://welcome.ai/content/biomatter-secures-18-million-to-advance-enzyme-design-efficiency)
- [Original source](https://www.bioxconomy.com/investment/biomatter-banks-18m-to-turn-enzyme-design-into-an-order-and-deliver-business)

---

Source: Welcome.AI | https://welcome.ai/content/biomatter-secures-18-million-to-advance-enzyme-design-efficiency